These data further suggest that despite the central role of SREBP1 in metabolism, it can be targeted independent of broader metabolic effectors such as AMPK and mTOR, promising a more specific interventional approach for cancer prevention with fewer side effects. The gene discussed is MTOR; the disease is cancer.